Dyax Corp. Announces Funded Research Agreement with Trubion Pharmaceuticals Inc. for Discovery of Therapeutic Proteins
Dyax Corp. has entered into a non-exclusive agreement with Trubion Pharmaceuticals Inc. (Trubion) in the fields of protein therapeutics and diagnostics discovery. Under the agreement, Dyax will utilize its proprietary phage display libraries for the discovery of compounds that bind with high affinity and specificity to Trubion's targets in the oncology and inflammation area. Dyax will receive upfront and FTE payments from Trubion, as well as technical and development milestone payments and royalties on net sales of any products that may result from Trubion's development and commercialization of binding regions from Dyax's libraries. The agreement also provides Trubion with an option to license Dyax's proprietary phage display libraries.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.